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Pssociation of Paraoxonase-1 Activity
nd Concentration With Angiographic
everity and Extent of Coronary Artery Disease
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arkku S. Nieminen, MD, PHD,* Mikko Syvänne, MD, PHD,* Marja-Riitta Taskinen, MD, PHD*
elsinki, Finland; and Geneva, Switzerland
OBJECTIVES The goal of this study was to examine the association between paraoxonase-1 (PON1) activity
and concentration and the severity and extent of coronary artery disease (CAD).
BACKGROUND Paraoxonase-1, a high-density lipoprotein-associated enzyme, is proposed to have an
antiatherogenic effect by protecting low-density lipoproteins against oxidation.
METHODS We studied PON1 activity and concentration in 107 patients with known or suspected CAD
referred for cardiac catheterization. Based on visual estimation of coronary angiograms,
subjects were classified as having no or mild CAD (50% stenosis) and significant CAD
(50% stenosis). Quantitative coronary angiography (QCA) was used to estimate the indexes
of severity, extent, and overall atheroma burden of CAD.
RESULTS We found lower values of PON1 activity and concentration (p  0.003 and p  0.016,
respectively) in the group with significant CAD as compared with the group with no or mild
CAD. The PON1 activity was significantly inversely correlated with CAD severity (r 
0.364, p  0.001), extent (r  0.221, p  0.022), and atheroma burden (r  0.277,
p  0.004). Similarly, PON1 concentration correlated with CAD severity (r  0.306, p 
0.001) and atheroma burden (r0.229, p 0.017). In multiple regression analysis, gender
and PON1 activity were significant determinants of the severity of CAD independently of
age, hypertension, smoking, abnormal glucose regulation, and high-density lipoprotein
cholesterol.
CONCLUSIONS Our results indicate that PON1 activity and concentration are lower in subjects with
significant CAD, and that there is a significant relationship between PON1 activity and
concentration and CAD assessed by QCA. (J Am Coll Cardiol 2006;47:2429–35) © 2006























cigh-density lipoproteins (HDLs) have a well-established
nverse relationship with the risk for coronary artery disease
CAD) (1,2). The oxidative modification of low-density
ipoprotein (LDL) is a key event in the initiation and
cceleration of atherosclerosis (3,4). As an antiatherogenic
ediator, HDL, aside from playing an important role in the
everse cholesterol transport, protects LDL against oxidation
5,6). The antioxidant property of HDL has been attributed in
art to the HDL-bound enzyme paraoxonase-1 (PON1)
7–9).
In vitro studies have shown the ability of PON1 to block
he accumulation of lipid peroxides in LDL, and concur-
ently to prevent the activation of monocytes by oxidized
DL (7,8). The most convincing data to link PON1 with
AD come from animal studies. In knockout mice lacking
he gene for PON1, atherosclerosis develops more rapidly
han in wild-type mice, whereas mice that overexpress
uman PON1 are resistant to atherosclerosis (10,11).
From the *Department of Internal Medicine, Division of Cardiology, Helsinki
niversity Central Hospital, Helsinki, Finland; and the †Clinical Diabetes Unit,
ivision of Endocrinology and Diabetology, University Hospital, Geneva,
witzerland. This work was supported by grants from the Helsinki University Central
ospital Research Foundation, the Finnish Foundation for Cardiovascular Research,
he Aarne Koskelo Foundation, the Wilhelm and Else Stockmann Foundation, and
he Swiss National Research Foundation.a
Manuscript received October 27, 2005; revised manuscript received January 7,
006, accepted January 9, 2006.Paraoxonase-1 has several genetic polymorphisms that
odify its activity and mass concentration (12). Hypothe-
ized differences in the ability of the polymorphic forms to
rotect oxidation of LDL have led to numerous studies
ttempting to determine the relationship between PON1
olymorphisms and CAD (13). These studies, irrespective
f polymorphism, have yielded apparently conflicting re-
ults. Investigating only an association between PON1
olymorphism and vascular disease may not adequately
ssess the protective effect of the enzyme, which has led to
he proposal that PON1 status (reflecting activity and
enotype) rather than genotype alone may be more impor-
ant in determining atherosclerosis risk (14).
To our knowledge there is only one prospective epidemi-
logic study, which has shown in middle-aged men that low
ON1 activity toward paraoxon is an independent risk
actor for coronary events (15). Similarly, few studies have
xamined the relationship between PON1 activity and
oncentration and angiographically proven CAD (14,16). In
ddition, no study has used rigorous computer-aided quan-
itative coronary angiographic (QCA) techniques to study
his question. The present study was therefore undertaken
o investigate, in a cohort of patients with known or
uspected CAD, the association between PON1 activity and
oncentration and the severity and extent of CAD based on
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total of 108 patients who underwent coronary angiogra-
hy for evaluation of known or suspected CAD were
ecruited in this study at Helsinki University Central Hos-
ital. Subjects with a history of coronary artery bypass
rafting, percutaneous coronary intervention, and those
ith insulin-dependent diabetes mellitus or significant renal
ailure (serum creatinine 150 mol/l) were excluded. One
atient was excluded because of severe hypertriglyceridemia
triglycerides 14 mmol/l). Written informed consent was
btained from all participants, and the study design was
pproved by the institutional ethics committee.
oronary angiography. Coronary angiography was per-
ormed using standard angiographic techniques. Angio-
raphic scoring was carried out by interventional cardiolo-
ists who were blinded to the study protocol. Mild CAD on
isual interpretation was defined as lumen diameter reduc-
ion 50%, and significant CAD as the presence of any
uminal stenosis 50%. Based on visual angiographic re-
ults, patients were divided into two subgroups such that
hose without any or with mild CAD comprised one group
nd those with 1 significantly affected coronary artery the
ther.
rame selection for quantitative coronary angiography.
oronary segments were analyzed in one angiographic view.
he frames for analysis were selected by one of the inves-
igators (M. G.). We classified coronary segments into four
ategories based on their location. The left main coronary
rtery was analyzed separately. Proximal parts of the anterior
escending, the left circumflex, and the right coronary
rteries were considered proximal segments. Mid segments
omprised the mid parts of the three main coronary arteries.
ll segments distal to the mid segments and 1.5 mm in
iameter were regarded as distal segments.
uantitative analysis of coronary angiograms. The cor-
nary angiograms were analyzed using Cardiovascular Mea-
urement System version 3.0 (Medis, Nuenen, the Nether-
ands) (17). All QCA analyses were carried out by one of the
nvestigators (M. G.).
easures of angiographic disease severity and extent.
he QCA-derived parameters were integrated into indexes,
s reported elsewhere in detail (18). Briefly, the severity
Abbreviations and Acronyms
apoA-I  apolipoprotein A-I
apoA-II  apolipoprotein A-II
apoB  apolipoprotein B
CAD  coronary artery disease
HDL  high-density lipoprotein
LDL  low-density lipoprotein
LpA-I  lipoprotein A-I
PON1  paraoxonase-1
QCA  quantitative coronary angiography
VLDL  very-low-density lipoproteinndex was defined as the average of the most severe stenoses un the left main, the left anterior descending, the left
ircumflex, and the right coronary arteries. Extent index was
alculated as the longitudinal percentage of coronary seg-
ents involved in stenosis (100   [stenosis lengths]/
[segment lengths]). Atheroma burden index was based on
laque area, reflecting both severity and extent, calculated
s: 100   (plaque areas)/ (segment lengths). One global
everity, extent, and atheroma burden index was determined
or each patient.
iochemical investigations. Blood samples were collected
month after coronary angiography after overnight fasting.
o avoid bias caused by medications, the patients were
equested to withhold any lipid-lowering drugs between the
ime of angiography and blood sampling; only highly
ardioselective and metabolically inert beta-blockers (mainly
isoprolol) were permitted.
Serum and ethylenediaminetetraacetic acid plasma were
eparated by centrifugation and stored at 80°C until
nalyzed. Cholesterol and triglyceride levels were measured
y automated enzymatic procedures (Hoffman-La Roche,
asel, Switzerland). The LDL, very low-density lipoprotein
VLDL), HDL, HDL2, and HDL3 cholesterol levels were
etermined after separating the lipoprotein fractions from
resh fasting sera by sequential ultracentrifugation (19).
oncentrations of apolipoproteins A-I, A-II, and B
apoA-I, apoA-II, and apoB) were measured by immuno-
urbidimetric methods using commercial kits (Boehringer-
annheim, Mannheim, Germany). Lipoprotein A-I
LpA-I) particles were quantified using a differential elec-
roimmunoassay (Sebia, Issy-les-Moulineaux, France) (20).
he concentration of LpA-I/A-II particles was calculated
y subtracting the concentration of LpA-I from the total
oncentration of apoA-I in serum.
All subjects underwent a 75-g standard oral glucose
olerance test, and blood specimens were collected 0 and
20 min after loading for determination of plasma glucose.
asting and postload glucose were measured by the hexoki-
ase method (Gluco-quant, Roche Diagnostic, Basel, Swit-
erland) using either a Hitachi 917 or a Modular analyzer
Hitachi Ltd., Tokyo, Japan).
araoxonase enzyme activity and serum concentration.
nzyme activity, using phenylacetate as the substrate, was
nalyzed in serum samples as described previously (21,22).
he serum concentration of paraoxonase-1 was assayed
sing a competitive enzyme-linked immunoassay (21).
efinition of risk factors. Body mass index was calculated
y dividing weight in kilograms by height in meters squared
kg/m2). Presence of hypertension was defined as current
se of antihypertensive drugs. Smoking status was recorded
s those who had never smoked and those who smoked one
r more cigarettes per day or had quit smoking. Abnormal
lucose regulation was defined as a history of known
iabetes or as a fasting plasma glucose 6.1 mmol/l or as
-h plasma glucose 7.8 mmol/l (23).
tatistical analyses. All statistical analyses were performed
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June 20, 2006:2429–35 PON1 Activity and Concentration and CAData are presented as frequencies or percentages for cate-
orical variables and as means  SEM for continuous
ariables, unless otherwise noted. Correlations were calcu-
ated by the univariate Spearman correlation coefficients.
etween-group differences were assessed by the Mann-
hitney U test. Furthermore, we performed a Kruskal-
allis test to compute means of severity and extent of CAD
or categories of PON1 activity and concentration, respec-
ively. For this endeavor, values of PON1 activity and
oncentration were categorized into tertiles (cutoff values for
ON1 activity were 74 and 97 U/ml, and for PON1
oncentration 84 and 108 g/ml). Multivariate linear re-
ression analysis was performed with the global percent
iameter stenosis index as dependent variable. A value of
 0.05 was considered statistically significant.
ESULTS
atient population. Demographic and clinical character-
stics are presented in Table 1. Typical atherosclerotic risk
actors and symptoms of CAD were prevalent. A high
ercentage of participants was taking aspirin, beta-blockers,
nd lipid-lowering drugs at baseline. The biochemical
haracteristics are summarized in Table 2.
ssociations between PON1 activity and concentration
nd clinical and lipid variables. In univariate correlation
nalyses, PON1 activity and concentration were signifi-
antly correlated with HDL cholesterol (p  0.005 for
oth), apoA-I (p  0.001 and p  0.006, respectively),
able 1. Demographic and Clinical Characteristics of the Study
opulation (n  107)
Variable
ge (yrs) 59.9 (6.9)
ale/female 80/27 (75/25)
ody mass index 27.6 (3.5)
ositive family history 78 (73)
urrent or former smoker 60 (56)
ypertension 62 (58)
bnormal glucose regulation 43 (40)
revious myocardial infarction 38 (36)
revious cerebrovascular disease 4 (4)









Angiotensin-converting enzyme inhibitor 31 (29)
Calcium channel blocker 21 (20)
Diuretics 14 (13)
Long-acting nitrates 49 (46)
ater treatment of coronary artery disease
Medical 37 (35)
Percutaneous coronary intervention 44 (41)
Coronary artery bypass grafting 26 (24)aalues are mean (SD) or n (%).poA-II (p  0.001 for both), and LpA-I/A-II (p  0.001
nd p  0.016, respectively). The HDL3 cholesterol level
as associated with borderline significance to PON1 activ-
ty and concentration (p  0.050 and p  0.065, respec-
ively). In addition, PON1 activity was associated with
ender (p  0.035), abnormal glucose regulation (p 
.045), and LpA-I (p  0.013). Gender (p  0.058),
ypertension (p 0.088), total cholesterol (p 0.097), and
pA-I (p  0.067) were associated with borderline signif-
cance to PON1 concentration (Table 3).
elationship between PON1 activity and concentration
nd the severity and extent of CAD. As outlined in Table
, PON1 activity was significantly associated with the
CA-derived global indexes for the severity (p  0.001),
xtent (p  0.022), and global atheroma burden (p 
.004). Similarly, PON1 concentration correlated signifi-
antly with global percent diameter stenosis index (p 
.001) and global atheroma burden index (p  0.017). The
orrelation with global extent index was of borderline
ignificance (p  0.097).
We found lower values of PON1 activity (84  2 U/ml
s. 100  5 U/ml, p  0.003) and PON1 concentration
94  3 g/ml vs. 110  6 g/ml, p  0.016), respectively,
n the group with significant CAD as compared with the
roup with no or mild CAD (Fig. 1).
Furthermore, mean values of QCA-derived global in-
exes for the severity, extent, and atheroma burden of CAD
ecreased in a stepwise manner across the tertiles of PON1
ctivity (Fig. 2). Similar associations were found when
ertiles of PON1 concentration instead of tertiles of PON1
able 2. Biochemical Characteristics and Other Study Variables
n  107)
Variable
otal cholesterol (mg/dl) 218  5
DL cholesterol (mg/dl) 51  1
DL2 cholesterol (mg/dl) 21  1
DL3 cholesterol (mg/dl) 31  1
DL cholesterol (mg/dl) 134  4
LDL cholesterol (mg/dl) 23  2
riglycerides (mg/dl) 84  5
poA-I (mg/dl) 135  2
poA-II (mg/dl) 36  1
poB (mg/dl) 123  3
pA-I (mg/dl) 49  1
pA-I/A-II (mg/dl) 85  2
asting plasma glucose (mg/dl) 214  4
-h glucose (mg/dl) 298  12
ON1 activity (U/ml) 87  2
ON1 concentration (g/ml) 97  3
lobal PDS index 31  1
lobal extent index 14  1
lobal atheroma burden index 7  0
alues are mean  SEM.
ApoA  apolipoprotein A; ApoB  apolipoprotein B; HDL  high-density
ipoprotein; LDL  low-density lipoprotein; LpA  lipoprotein A; PDS  percent
iameter stenosis index; PON1  paraoxonase-1; VLDL  very low-density
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PON1 Activity and Concentration and CAD June 20, 2006:2429–35ultivariate regression analyses. To establish indepen-
ent determinants of global percent diameter stenosis index,
e performed a linear regression analysis controlled for age,
ender, hypertension, abnormal glucose regulation, smoking
tatus, HDL cholesterol, and PON1 activity. In the final
odel that explained 25.1% of variation of global percent
iameter stenosis index, the most important determinants
ere gender (p  0.001) and PON1 activity (p  0.016)
Table 4). The outcome was similar when replacing HDL
holesterol with HDL2 cholesterol, HDL3 cholesterol,
poA-I, or apoA-II (data not shown).
ISCUSSION
n this cohort of patients undergoing elective coronary
ngiography, there was a significant relationship between
ON1 activity and concentration and coronary atheroscle-
osis expressed as quantitative angiographic indexes of
everity, extent, and overall atheroma burden of CAD.
Multiple studies have examined the association between
ON1 polymorphisms and CAD. A recent meta-analysis
sing all 43 available studies of the PON1 polymorphisms
nvolving 11,212 CAD cases and 12,786 controls suggested
hat the link between PON1 polymorphism and CAD is at
est weak (13). However, the vast majority of the studies
ave not assessed the quality of PON1, i.e., its activity and
oncentration in the serum.
There is, so far, only limited information available about
he association between directly measured PON1 activity
nd concentration and angiographically proven CAD. Al-
able 3. Correlation Coefficients Between PON1 Activity and







r p r p
ge (yrs) 0.150 0.123 0.132 0.175
ender 0.204 0.035 0.184 0.058
ypertension 0.100 0.307 0.165 0.088
urrent or former smoker 0.112 0.250 0.143 0.142
bnormal glucose regulation 0.194 0.045 0.115 0.237
otal cholesterol 0.075 0.444 0.161 0.097
DL cholesterol 0.268 0.005 0.270 0.005
DL2 cholesterol 0.150 0.124 0.170 0.080
DL3 cholesterol 0.190 0.050 0.179 0.065
DL cholesterol 0.034 0.728 0.044 0.653
LDL cholesterol 0.049 0.618 0.056 0.565
riglycerides 0.084 0.387 0.107 0.272
poA-I 0.355 0.001 0.263 0.006
poA-II 0.368 0.001 0.386 0.001
poB 0.034 0.725 0.080 0.412
pA-I 0.240 0.013 0.178 0.067
pA-I/A-II 0.304 0.001 0.232 0.016
lobal PDS index 0.364 0.001 0.306 0.001
lobal extent index 0.221 0.022 0.161 0.097
lobal atheroma burden index 0.277 0.004 0.229 0.017
bbreviations as in Table 2.hough the difference did not reach statistical significance,
(
czarsiz et al. (16) found that PON1 activity of patients with
AD (n  68) was lower than that of patients without
AD (n  33) and control subjects (n  24). Further,
ackness et al. (14) showed that PON1 activity and PON1
oncentrations were lower in subjects with CAD than in
ontrol subjects. Notably, the result was independent of the
ON1 genotype, and the investigators concluded that the
uality of the PON1 enzyme is a more important factor in
AD than is the PON1 gene.
The QCA was developed to overcome the limitations of
isual interpretation of coronary angiograms, but QCA has
een applied in only one study comparing PON1 polymor-
hisms and the angiographic severity and extent of CAD
24). In a report from the WISE study including 711
omen, Chen et al. (24) did not find any significant
ssociation between the PON polymorphisms and stenosis
everity in either white or black women. However, when
igure 1. Box plot shows median (horizontal lines), 25th to 75th
ercentiles (boxes), and 95th percentiles (whiskers) of paraoxonase-1
PON1) activity (A) and PON1 concentration (B) by visual angiographic























































and global atheroma burden index (C), respectively. For definition of the
indexes, see the Methods section.
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June 20, 2006:2429–35 PON1 Activity and Concentration and CADatients with significant CAD (50% stenosis) were strat-
fied into groups with one-, two-, or three-vessel CAD,
ignificant associations were noted between PON polymor-
hisms and the number of diseased vessels in white but not
n black subjects. In contrast to our study, the study of Chen
t al. (24) included only women, and data of PON1 activity
nd concentration were not available.
This study is, to our knowledge, the first to present data
n PON1 activity and concentration in patients with CAD
easured both by visual interpretation and by refined
omputer-assisted scoring of coronary angiograms. Our
esults show that PON1 activity and concentration were
ower in patients with significant CAD. Moreover, PON1
ctivity and concentration were significantly associated
ith the indexes for global severity, extent, and atheroma
urden of CAD. We found a stepwise decrease in these
CA-derived indexes across the tertiles of PON1 activity
nd concentration. Subjects in the lowest tertile of PON1
ctivity and concentration, respectively, had a more
evere and extensive disease than subjects in the highest
ertile.
Activity and concentration of PON1 can vary up to
0-fold in human populations (25,26). Part of this variabil-
ty is explained by the polymorphism of PON1 gene because
f an amino acid substitution at 192 (27). The R allele
arginine at position 192) displays several-fold higher activ-
ty toward paraoxon hydrolysis than the Q allele (glutamine
t position 192), and may have a greater capacity to protect
gainst copper ion-induced LDL oxidation (28). In con-
rast, phenylacetate hydrolysis is largely unaffected by the
olymorphism, and has been used as a surrogate for protein
oncentrations (29). Thus the use of phenylacetate, as in
ur study, provides a better overall indication of PON1
ctivity levels. However, which PON1 substrates should
e used in correlative studies with cardiovascular disease
s unresolved (30).
Although PON1 activity and concentration are deter-
ined genetically, various factors, such as diet, lifestyle, and
nvironmental factors, can influence PON1 activity and/or
oncentration. Degraded cooking oil has been reported to
ower serum PON1 levels in humans (31). Dietary polyphe-
ols increase PON1 activity, as does moderate alcohol
ntake (32,33). Smoking is known to decrease serum PON1
ctivity (34). Recent evidence shows that exposure to
nvironmental chemicals can inhibit PON1 activity (35,36).
urthermore, low serum PON1 activity independent of
enotype has been reported in diseases associated with
ccelerated atherogenesis, such as diabetes mellitus, hyper-
holesterolemia, and renal failure (37–39).
In human serum, most if not all of the paraoxonase
ctivity is associated with HDL. Paraoxonase is present in a
istinct HDL subspecies containing apoA-I and clusterin or
po J (40). La Du et al. (41) showed that it is extremely
ifficult to remove apoA-I from PON1 during purification
rom human serum, which has led to the suggestion thatigure 2. Relationship between paraoxonase-1 (PON1) activity tertile by
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PON1 Activity and Concentration and CAD June 20, 2006:2429–35ine with population studies that have shown a statistical
ssociation of PON1 activity with HDL cholesterol,
poA-I, and apoA-II (38,41,42).
Interestingly, our results in the multivariable analyses
ndicate that PON1 activity is a significant determinant
f the severity of CAD independently of HDL choles-
erol, HDL2 cholesterol, HDL3 cholesterol, apoA-I, and
poA-II. Recently, Rozek et al. (43) reported that in 91 male
ubjects with severe carotid artery disease and 184 control
ubjects, PON1 activity in the case group was strongly
orrelated with LDL and VLDL cholesterol in the absence
f the expected HDL3 and apoA-I associations. In the
resent study, however, we could not confirm their findings,
ossibly in part because of the different study design and
opulation. Furthermore, in our multivariate analyses, the
utcome was similar when LDL and/or VLDL cholesterol
ere added in the model (data not shown), suggesting that
ON1 activity indeed has an independent and important
ole in the pathogenesis of coronary atherosclerosis.
In summary, we have shown that PON1 activity toward
henylacetate and PON1 concentration are lower in sub-
ects with significant CAD, and there is a significant
elationship between activity and concentration of PON1
nd the severity and extent of coronary atherosclerosis. The
esult show the relevance of PON1 activity and concentra-
ion for describing associations between atherosclerotic
isease and the enzyme. More importantly, the study shows
ow the protective role of HDL could be modulated by its
omponents such that equivalent serum concentrations of
DL cholesterol may not equate with an equivalent poten-
ial protective capacity.
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Adjusted multiple R2 and F ratio 0.2
*Log indicates logarithmic transformation of the variable.
Abbreviations as in Table 2.inland. Email: marit.graner@hus.fi.EFERENCES
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